Androgen receptor network in prostate cancer (WP2263)
Homo sapiens
The androgen receptor (AR), also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a type of nuclear receptor that is activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. The main function of the androgen receptor is as a DNA-binding transcription factor that regulates gene expression. The AR is important for therapeutic target in prostate cancer, thus many different inhibitors have been developed, primarily targeting the ligand binding domain of the protein, while inhibitors that target the N-terminal domain of the protein are still under development. Description source: [https://en.wikipedia.org/wiki/Androgen_receptor Wikipedia]
Authors
Phillip Febbo , Robertbaertsch , Daniela Digles , Egon Willighagen , Kristina Hanspers , Alex Pico , Martina Summer-Kutmon , Friederike Ehrhart , Lauren J. Dupuis , and Eric WeitzActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
CPTAC DiseasesAnnotations
Disease Ontology
prostate cancerPathway Ontology
cancer pathway prostate cancer pathwayLabel | Type | Compact URI | Comment |
---|---|---|---|
17-alpha-OH-Progesterone | Metabolite | hmdb:HMDB0000374 | |
Dihydrotestosterone | Metabolite | hmdb:HMDB0002961 | |
Androstenedione | Metabolite | cas:63-05-8 | |
Progesterone | Metabolite | cas:57-83-0 | |
Estradiol | Metabolite | cas:57-91-0 | |
Testosterone | Metabolite | cas:58-22-0 | |
Estrone | Metabolite | cas:53-16-7 | |
Androstenediol | Metabolite | hmdb:HMDB0005849 | |
dehydroepiandrosterone | Metabolite | cas:53-43-0 | |
Pregnenolone | Metabolite | cas:145-13-1 | |
17-alpha-OH-Pregnenolone | Metabolite | hmdb:HMDB0000363 | |
Cholesterol | Metabolite | cas:57-88-5 | |
SPINK1 | GeneProduct | ncbigene:6690 | From Entrez Gene: The protein encoded by this gene is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. It is thought to function in the prevention of trypsin-catalyzed premature activation of zymogens within the pancreas and the pancreatic duct. Mutations in this gene are associated with hereditary pancreatitis and tropical calcific pancreatitisAssociation with Prostate Cancer - Chinnaiyan Lab Cancer Cell Paper - ETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers (∼10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers. |
SPRY1 | GeneProduct | ncbigene:10252 | |
AR | GeneProduct | ncbigene:367 | AR |
HSD3B2 | GeneProduct | ncbigene:3284 | |
CYP17A1 | GeneProduct | ncbigene:1586 | |
HSD3B1 | GeneProduct | ncbigene:3283 | |
HSD17B7 | GeneProduct | ncbigene:51478 | |
Hydroxyprogesterone aldolase | GeneProduct | eccode:4.1.2.30 | |
F13B | GeneProduct | ncbigene:2165 | |
HSD17B4 | GeneProduct | ncbigene:3295 | |
Steroid-19-Hydroxylase | GeneProduct | ensembl:ENSG00000120054 | |
HSD17B2 | GeneProduct | ncbigene:3294 | |
HSD17B3 | GeneProduct | ncbigene:3293 | |
HSD17B1 | GeneProduct | ncbigene:3292 | |
p38 | GeneProduct | ensembl:ENSG00000112062 | |
ATF1 | GeneProduct | ncbigene:466 | |
ARID1A | GeneProduct | ncbigene:8289 | |
PLK1 | GeneProduct | ensembl:ENSG00000166851 | |
CDC25B | GeneProduct | ensembl:ENSG00000101224 | |
CDC25A | GeneProduct | ensembl:ENSG00000164045 | |
TMPRSS2 | GeneProduct | hgnc:7113 | |
KLK3 | GeneProduct | ncbigene:354 | |
KLK2 | GeneProduct | ncbigene:3817 | |
NDRG1 | GeneProduct | ncbigene:10397 | |
ABCC4 | GeneProduct | ncbigene:10257 | |
ERG | GeneProduct | ncbigene:2078 | Fusion partner with TMPRSS2 in about 40% of prostate cancers |
ETV4 | GeneProduct | ncbigene:2118 | Fusion partner with TMPRSS2 in about 40% of prostate cancers |
ARID1B | GeneProduct | ncbigene:57492 | |
SMARCA4 | GeneProduct | ncbigene:6597 | |
SMARCC1 | GeneProduct | ncbigene:6599 | |
SMARCC2 | GeneProduct | ncbigene:6601 | |
SMARCD1 | GeneProduct | ncbigene:6602 | |
SMARCD2 | GeneProduct | ncbigene:6603 | |
SMARCD3 | GeneProduct | ncbigene:6604 | |
ACTL6A | GeneProduct | ncbigene:86 | |
ACTL6B | GeneProduct | ncbigene:51412 | |
MAP2K1 | GeneProduct | ncbigene:5604 | |
MAP4K1 | GeneProduct | ncbigene:11184 | |
STAT3 | GeneProduct | ncbigene:6774 | |
HGF | GeneProduct | ncbigene:3082 | |
RAP1A | GeneProduct | ncbigene:5906 | |
PTPN11 | GeneProduct | ncbigene:5781 | |
PTEN | GeneProduct | ncbigene:5728 | |
MAP2K2 | GeneProduct | ncbigene:5605 | |
MAPK1 | GeneProduct | ncbigene:5594 | |
CRKL | GeneProduct | ncbigene:1399 | |
HRAS | GeneProduct | ncbigene:3265 | |
FOS | GeneProduct | ncbigene:2353 | |
DOCK1 | GeneProduct | ncbigene:1793 | Interim Symbol: Dock1 predicted and Name: dedicator of cyto-kinesis 1 (predicted) |
PXN | GeneProduct | ncbigene:5829 | |
RAPGEF1 | GeneProduct | ncbigene:2889 | |
RAF1 | GeneProduct | ncbigene:5894 | |
SOS1 | GeneProduct | ncbigene:6654 | Son of sevenless homolog 1 (Drosophila) (predicted) |
Met | GeneProduct | ncbigene:24553 | |
JUN | GeneProduct | ncbigene:3725 | |
PTK2B | GeneProduct | ncbigene:2185 | |
PIK3CA | GeneProduct | ncbigene:5290 | |
PAK1 | GeneProduct | ncbigene:5058 | |
ELK1 | GeneProduct | ncbigene:2002 | |
MAPK8 | GeneProduct | ncbigene:5599 | |
CRK | GeneProduct | ncbigene:1398 | |
GAB1 | GeneProduct | ncbigene:2549 | |
RAP1B | GeneProduct | ncbigene:5908 | |
RASA1 | GeneProduct | ncbigene:5921 | |
GRB2 | GeneProduct | ncbigene:2885 | |
MAPK3 | GeneProduct | ncbigene:5595 | |
MYC | GeneProduct | ncbigene:4609 | |
EIF4EBP1 | GeneProduct | ncbigene:1978 | From Entrez Gene: The protein encoded by this gene is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. It is thought to function in the prevention of trypsin-catalyzed premature activation of zymogens within the pancreas and the pancreatic duct. Mutations in this gene are associated with hereditary pancreatitis and tropical calcific pancreatitisAssociation with Prostate Cancer - Chinnaiyan Lab Cancer Cell Paper - ETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers (∼10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers. |
SPRY2 | GeneProduct | ncbigene:10253 | |
MYC | Protein | uniprot:P01106 | |
FOXA1 | Protein | ncbigene:3169 | DNA licensing factor for AR. Frequently occupies regions in enhancers with DNA recognition elements close to AR ARE |
SPINK1 | Protein | uniprot:D6RIU5 | |
FKBP5 | Protein | ncbigene:2289 | |
TSC1 | Protein | uniprot:Q92574 | |
AR | Protein | ncbigene:367 | AR |
RAD50 | Protein | uniprot:Q92878 | |
MSH6 | Protein | uniprot:P52701 | |
CDC2 | Protein | uniprot:P06493 | Oncogene |
BRCA1 | Protein | uniprot:P38398 | Phosphorylated |
CASP8 | Protein | uniprot:Q14790 | |
ATR | Protein | uniprot:Q13535 | |
BARD1 | Protein | uniprot:Q99728 | |
CASP9 | Protein | uniprot:P55211 | |
RB1 | Protein | uniprot:P06400 | |
SMAD3 | Protein | uniprot:P84022 | |
NOXA1 | Protein | uniprot:Q86UR1 | |
BLM | Protein | uniprot:P54132 | |
Q8NBS1 | Protein | uniprot:Q8NBS1 | |
CDK4 | Protein | uniprot:P11802 | |
MRE11 | Protein | uniprot:P49959 | |
STAT1 | Protein | uniprot:P42224 | |
BCL2 | Protein | uniprot:P10415 | |
AKT1 | Protein | uniprot:P31749 | |
CASP3 | Protein | uniprot:P42574 | |
TP53 | Protein | uniprot:P04637 | |
CHK2 | Protein | uniprot:O96017 | Phosphrylated |
JAK1 | Protein | uniprot:P23458 | |
MSH2 | Protein | uniprot:P43246 | |
BAX | Protein | uniprot:Q07812 | |
PRKDC | Protein | uniprot:P78527 | |
CHK1 | Protein | uniprot:O14757 | |
BRCA1 | Protein | uniprot:P38398 | |
MMP1 | Protein | uniprot:P03956 | |
CDK2 | Protein | uniprot:P24941 | |
BAD | Protein | uniprot:Q92934 | |
ATM | Protein | uniprot:Q13315 | |
SMAD2 | Protein | uniprot:Q15796 | Tumor supressor |
E2F1 | Protein | uniprot:Q01094 | |
MDM2 | Protein | uniprot:Q00987 | Oncogene |
SP1 | Protein | ncbigene:6667 | DNA licensing factor for AR. Frequently occupies regions in enhancers with DNA recognition elements close to AR ARE |
TSC2 | Protein | uniprot:P49815 | |
RHEB | Protein | uniprot:Q15382 | |
MTOR | Protein | uniprot:P42345 | |
RICTOR | Protein | ncbigene:253260 | |
RPTOR | Protein | uniprot:Q8N122 | |
4EBP1 | Protein | uniprot:Q13541 | |
EIF4E1B | Protein | uniprot:A6NMX2 | |
CCND1 | Protein | uniprot:P24385 |
References
- The role of SPINK1 in ETS rearrangement-negative prostate cancers. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al. Cancer Cell. 2008 Jun;13(6):519–28. PubMed Europe PMC Scholia
- MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Schramedei K, Mörbt N, Pfeifer G, Läuter J, Rosolowski M, Tomm JM, et al. Oncogene. 2011 Jun 30;30(26):2975–85. PubMed Europe PMC Scholia
- MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, et al. PLoS One. 2011 Apr 22;6(4):e19139. PubMed Europe PMC Scholia